T-1101 / Taivex Therapeutics Corporation - LARVOL DELTA

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Taivex Therapeutics Corporation | Trial completion date: Jul 2024 ➔ Jul 2026 | Trial primary completion date: Jul 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

T-1101: A novel first-in-class oral Hec1/Nek2 inhibitor for cancer therapy (KSMO 2024) - No abstract available

Oncology

Trial in progress: Phase 1 dose escalation study of T-1101, a first-in-class oral Hec1/Nek2 inhibitor, in patients with advanced refractory solid tumors (AACR 2024) - P1 | "Moreover, T-1101 has synergistic activity when combined with other anticancer drugs such as doxorubicin, topotecan and paclitaxel etc. Clinically, oral powder for constitution (OPC) form was first used in the initial study. Cohorts 1 (100 mg/day) 2 (200 mg/day) and 3 (225 mg/day) have been completed without DLT. As of November 2023, the trial remains open to enrollment."

Clinical • Metastases • P1 data • Breast Cancer • Oncology • Solid Tumor

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Taivex Therapeutics Corporation | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Jul 2024 | Trial primary completion date: Jun 2023 ➔ Jul 2024

Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Taiwei Biotech successfully developed two new anti-cancer drugs to apply for phase II clinical trials by the end of this year [Google translation] (money.udn.com) - "Zhao Yusheng, general manager of Taiwei Biotechnology, said that the company currently has four First-in-Class/ Best-in-Class Targeted anti-cancer drugs, including T-1101 and T-1201, two new anti-cancer drugs with different mechanisms of action, are expected to be put forward for Phase II clinical trials by the end of this year....T-1501 is undergoing preclinical toxicology experiments. It is expected to apply for IND in Taiwan and the United States early next year and carry out the first phase of clinical trials."

IND • New P1 trial • New P2 trial • Oncology • Solid Tumor

Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Taivex Therapeutics Corporation | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Jun 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • Oncology • Solid Tumor